Member Posts > Cardiol Therapeutics' CRD-38's Role in Advancing Heart Failure Treatment
Mitochondrial dysfunction contributes significantly to heart failure progression by impairing ATP production and increasing oxidative stress, leading to cardiomyocyte death. CRD-38, developed by Cardiol Therapeutics, is a promising cannabidiol-based therapy designed to target these dysfunctions. Its mechanism of action includes reducing oxidative stress through CBD's anti-inflammatory effects and stimulating mitochondrial biogenesis via PPAR-γ activation. Preclinical studies indicate that CRD-38 enhances mitochondrial respiration, decreases oxidative damage, and improves cardiac function. Given its potential to address metabolic inefficiencies in HFpEF patients, CRD-38 could revolutionize heart failure treatment. Cardiol Therapeutics is working toward regulatory approvals to bring this novel therapy into clinical trials, marking a significant step forward in heart failure research and innovation.

#CardiolTherapeutics #HeartFailureTreatment #BiotechInvesting #ClinicalTrials #CBDTherapeutics #HeartHealth #MedicalInnovation #PharmaceuticalBreakthroughs #CRD38